CD68 and infectious otitis media: In colitis-associated tumorigenesis, in contrast to WT mice, all CD68–mEPRAP transgenic mice survived the AOM/DSS treatment (Fig 5G), and CD68–mEPRAP transgenic mice developed fewer polyps (Fig 5H and 5I).